ICU Medical, Inc. (NASDAQ:ICUI – Get Free Report) has earned an average rating of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating, four have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $192.80.
Several research firms have recently commented on ICUI. Raymond James Financial reiterated a “strong-buy” rating and issued a $200.00 price objective on shares of ICU Medical in a report on Friday, August 7th. Weiss Ratings upgraded ICU Medical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Sanford C. Bernstein lowered ICU Medical to a “market perform” rating in a research report on Monday, June 15th. BTIG Research boosted their price objective on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Jefferies Financial Group raised ICU Medical to a “strong-buy” rating in a research note on Thursday, May 7th.
ICU Medical Price Performance
ICU Medical (NASDAQ:ICUI – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.46. ICU Medical had a net margin of 1.39% and a return on equity of 7.91%. The company had revenue of $547.88 million for the quarter, compared to analysts’ expectations of $533.44 million. During the same quarter last year, the company earned $2.10 EPS. The firm’s revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Equities research analysts expect that ICU Medical will post 7.19 EPS for the current year.
Insider Activity
In other ICU Medical news, Director Elisha W. Finney sold 378 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $182.48, for a total value of $68,977.44. Following the sale, the director owned 4,871 shares of the company’s stock, valued at $888,860.08. This trade represents a 7.20% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel Woolson sold 5,417 shares of the firm’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total transaction of $982,264.61. Following the completion of the sale, the vice president directly owned 17,062 shares in the company, valued at approximately $3,093,852.46. This trade represents a 24.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 16,974 shares of company stock valued at $3,085,844 in the last three months. Corporate insiders own 2.10% of the company’s stock.
Institutional Trading of ICU Medical
A number of institutional investors have recently modified their holdings of the company. Maryland State Retirement & Pension System increased its holdings in ICU Medical by 2.0% during the 4th quarter. Maryland State Retirement & Pension System now owns 3,619 shares of the medical instruments supplier’s stock valued at $516,000 after purchasing an additional 70 shares during the period. California Public Employees Retirement System lifted its holdings in ICU Medical by 0.3% in the 1st quarter. California Public Employees Retirement System now owns 30,461 shares of the medical instruments supplier’s stock worth $3,934,000 after buying an additional 90 shares during the period. Oregon Public Employees Retirement Fund grew its position in shares of ICU Medical by 1.8% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 5,631 shares of the medical instruments supplier’s stock worth $803,000 after buying an additional 100 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of ICU Medical by 11.6% in the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after buying an additional 101 shares during the last quarter. Finally, Lido Advisors LLC increased its stake in shares of ICU Medical by 4.5% during the fourth quarter. Lido Advisors LLC now owns 2,479 shares of the medical instruments supplier’s stock valued at $354,000 after buying an additional 106 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.
ICU Medical Company Profile
ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.
Featured Stories
- Five stocks we like better than ICU Medical
- 2 Biotech Stocks Shaping Up for Major Breakouts
- 3 Stocks Came Roaring Back—Now They’re Flashing Warning Signs
- 3 Beaten-Down Stocks That Haven’t Gotten the Message About the S&P 500’s Record Run
- Darden Restaurants Just Hit a 52-Week High–Is the Olive Garden Comeback Story Legit?
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.
